On 24 April 2019, orphan designation (EU/3/13/1185) was granted by the European Commission to Alexion Europe S.A.S., France, for eculizumab for the treatment of neuromyelitis optica spectrum disorders.
Eculizumab for treatment of neuromyelitis optica spectrum disorders has been authorised in the EU as Soliris since 26 August 2019.
The sponsor’s address was updated in November 2019.
|Disease / condition||
Treatment of neuromyelitis optica spectrum disorders
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.